Next-generation sequencing (NGS) enables researchers to better understand the biology that drives cancer predisposition and proliferation. These insights can support the development of targeted therapeutics and multi-analyte tumor analysis. NGS also opens the door for discovery of novel methods to monitor cancer treatment and recurrence.
lllumina brings innovation to cancer drug development by offering comprehensive genomic solutions working in collaboration with leading pharmaceutical providers.
Some NGS discoveries have become the basis for companion diagnostics and laboratory developed tests (LDT) now in use in molecular diagnostic laboratories worldwide. These laboratories are now faced with an evolving landscape of regulations and reimbursement strategies for NGS oncology testing.
We spoke with several key opinion leaders about the ongoing challenges and potential of NGS in oncology.Read Interview
As targeted therapies make their way through pharmaceutical pipelines, the need for comprehensive tumor profiling is increasing.Learn More
NGS helps drug developers to explore genomic variation. This informs target discovery, validation, and clinical development.Learn More